SCHEMBL896217

SCHEMBL896217

O=CCCc1ccc(Cl)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.50
LMNA P02545 1/20 0.47
MAOB P27338 1/20 0.43
HSD17B10 Q99714 1/20 0.42
IDO1 P14902 1/20 0.42
AOC3 Q16853 1/20 0.42
HTR3E A5X5Y0 1/20 0.41
HTR3B O95264 1/20 0.41
HTR3A P46098 1/20 0.41
HTR3D Q70Z44 1/20 0.41
HTR3C Q8WXA8 1/20 0.41
MIF P14174 1/20 0.41
KCNH2 Q12809 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094552 0.87 KCNH2 (0.46) TAAR1LMNAMAOBHSD17B10IDO1
SCHEMBL9671868 0.87 HIF1A (0.37) LMNACA2
SCHEMBL3245743 0.86 TAAR1 (0.46) TAAR1LMNAMAOBHTR3EHTR3B
SCHEMBL5543511 0.85 HDAC3 (0.49) TAAR1LMNAMAOBHTR3EHTR3B
SCHEMBL5547783 0.83 HDAC3 (0.47) TAAR1LMNAHTR3EHTR3BHTR3A
SCHEMBL2091006 0.83 KCNH2 (0.46) TAAR1LMNAMAOBHSD17B10IDO1
SCHEMBL10012084 0.80 HRH3 (0.41) LMNAMAOBHDAC2HDAC8
SCHEMBL16596062 0.80 CYP2A6 (0.42) LMNAHDAC1HDAC2IGF1RALOX15
SCHEMBL14884585 0.80 CHKA (0.46) TAAR1LMNAMAOB
Glutaral SCHEMBL9719285 0.78 IGF1R (0.43) TAAR1LMNAMAOBHTR3EHTR3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 301 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10787484-B2 Compositions and methods for treating cardiovascular disease GENENTECH, INC. (US) 2020-09-29 US claimed
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE GENENTECH, INC. (US) 2019-06-13 US claimed
EP-2763987-B1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE AS FUNGICIDALS BAYER CROPSCIENCE AG (DE) 2018-07-18 EP claimed
EP-2763993-B1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE BAYER IP GMBH (DE) 2017-04-19 EP claimed
US-9023844-B2 Heterocyclylpyri (mi) dinylpyrazole as fungicidals BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-05-05 US claimed
US-20140364456-A1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-12-11 US claimed
US-20140256677-A1 HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-11 US claimed
CN-104039785-A Heterocyclylpyrazoles as fungicides BAYER IP GMBH 2014-09-10 CN claimed
EP-2763993-A1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE Bayer Intellectual Property GmbH (DE) 2014-08-13 EP claimed
EP-2763987-A1 HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS Bayer Intellectual Property GmbH (DE) 2014-08-13 EP claimed
CN-101679591-A Radiation-crosslinking and thermally crosslinking PU systems based on isocyanate-reactive block copolymers BAYER MATERIALSCIENCE AG 2010-03-24 CN claimed
CN-101679574-A Radiation-and thermally-crosslinking polyurethane systems comprising iminooxadiazinedione BAYER MATERIALSCIENCE AG 2010-03-24 CN claimed
CN-101657483-A Radiation-crosslinking and thermally crosslinking PU systems based on poly (epsilon-caprolactone) polyester polyols BAYER MATERIALSCIENCE AG 2010-02-24 CN claimed
WO-1995024424-A1 CYCLIC PEPTIDE LHRH ANTAGONISTS ABBOTT LABORATORIES (US) 1995-09-14 WO claimed
US-5140009-A Stable against proteolytic enzymes; anticarcinogenic agents; urogenital disorders TAP PHARMACEUTICALS, INC. (US) 1992-08-18 US claimed
EP-0480918-A1 REDUCED SIZE LHRH ANALOGS ABBOTT LABORATORIES (US) 1992-04-22 EP claimed
EP-0480918-A4 REDUCED SIZE LHRH ANALOGS. ABBOTT LAB (US) 1991-06-04 EP claimed
EP-0417454-A2 Reduced size LHRH analogs ABBOTT LABORATORIES (US) 1991-03-20 EP claimed
WO-1989007451-A1 REDUCED SIZE LHRH ANALOGS ABBOTT LABORATORIES (US) 1989-08-24 WO claimed
EP-0328089-A2 Reduced size LHRH analogs ABBOTT LABORATORIES (US) 1989-08-16 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256677-A1 HETEROCYCLYLPYRI (MI) DINYLPYRAZOLE AS FUNGICIDALS CCNY, NQO2, H1-0 TAAR1 3592/4885LMNA 958/4885MAOB 180/4885
US-10787484-B2 Compositions and methods for treating cardiovascular disease PCSK9, PCSK7, PCSK6 TAAR1 4623/4885LMNA 136/4885MAOB 1282/4885
US-20190177366-A1 COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE PCSK9, PCSK7, PCSK6 TAAR1 4623/4885LMNA 136/4885MAOB 1282/4885
US-20140364456-A1 HETEROCYCLYLPYRI(MI)DINYLPYRAZOLE H1-0, NQO2, CCNI TAAR1 3449/4885LMNA 744/4885MAOB 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.